<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36309510</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>29</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Cellular glycan modification by B3GAT1 broadly restricts influenza virus infection.</ArticleTitle><Pagination><StartPage>6456</StartPage><MedlinePgn>6456</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6456</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-022-34111-0</ELocationID><Abstract><AbstractText>Communicable respiratory viral infections pose both epidemic and pandemic threats and broad-spectrum antiviral strategies could improve preparedness for these events. To discover host antiviral restriction factors that may act as suitable targets for the development of host-directed antiviral therapies, we here conduct a whole-genome CRISPR activation screen with influenza B virus (IBV). A top hit from our screen, beta-1,3-glucuronyltransferase 1 (B3GAT1), effectively blocks IBV infection. Subsequent studies reveal that B3GAT1 activity prevents cell surface sialic acid expression. Due to this mechanism of action, B3GAT1 expression broadly restricts infection with viruses that require sialic acid for entry, including Victoria and Yamagata lineage IBVs, H1N1/H3N2 influenza A viruses (IAVs), and the unrelated enterovirus D68. To understand the potential utility of B3GAT1 induction as an antiviral strategy in vivo, we specifically express B3GAT1 in the murine respiratory epithelium and find that overexpression is not only well-tolerated, but also protects female mice from a lethal viral challenge with multiple influenza viruses, including a pandemic-like H1N1 IAV. Thus, B3GAT1 may represent a host-directed broad-spectrum antiviral target with utility against clinically relevant respiratory viruses.</AbstractText><CopyrightInformation>© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Trimarco</LastName><ForeName>Joseph D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0001-5463-7144</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nelson</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaparian</LastName><ForeName>Ryan R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wells</LastName><ForeName>Alexandra I</ForeName><Initials>AI</Initials><Identifier Source="ORCID">0000-0001-8178-0376</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Infectious Diseases, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Nathan B</ForeName><Initials>NB</Initials><Identifier Source="ORCID">0000-0002-0685-722X</Identifier><AffiliationInfo><Affiliation>Complex Carbohydrate Research Center, The University of Georgia, Athens, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azadi</LastName><ForeName>Parastoo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Complex Carbohydrate Research Center, The University of Georgia, Athens, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyne</LastName><ForeName>Carolyn B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0002-1884-6309</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heaton</LastName><ForeName>Nicholas S</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-5307-3428</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA. nicholas.heaton@duke.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. nicholas.heaton@duke.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 AI149866</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 GM137782</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009111</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>GZP2782OP0</RegistryNumber><NameOfSubstance UI="D019158">N-Acetylneuraminic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011134">Polysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.17</RegistryNumber><NameOfSubstance UI="D014453">Glucuronosyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019158" MajorTopicYN="N">N-Acetylneuraminic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009976" MajorTopicYN="Y">Orthomyxoviridae Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011134" MajorTopicYN="N">Polysaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014453" MajorTopicYN="N">Glucuronosyltransferase</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>30</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36309510</ArticleId><ArticleId IdType="pmc">PMC9617049</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34111-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-022-34111-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227606</ArticleId><ArticleId IdType="pubmed">30496103</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard M, Fouchier RA. Influenza A virus transmission via respiratory aerosols or droplets as it relates to pandemic potential. FEMS Microbiol. Rev. 2016;40:68–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006288</ArticleId><ArticleId IdType="pubmed">26385895</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung NHL. Transmissibility and transmission of respiratory viruses. Nat. Rev. Microbiol. 2021;19:528–545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7982882</ArticleId><ArticleId IdType="pubmed">33753932</ArticleId></ArticleIdList></Reference><Reference><Citation>Houser K, Subbarao K. Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015;17:295–300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362519</ArticleId><ArticleId IdType="pubmed">25766291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner AM, et al. Unraveling the mysteries of acute flaccid myelitis: scientific opportunities and priorities for future research. Clin. Infect. Dis. 2021;72:2044–2048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315125</ArticleId><ArticleId IdType="pubmed">32964217</ArticleId></ArticleIdList></Reference><Reference><Citation>Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat. Med. 2021;27:591–600.</Citation><ArticleIdList><ArticleId IdType="pubmed">33846611</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Food and Drug Administration. Influenza (Flu) Antiviral Drugs and Related Information, &lt;https://www.fda.gov/drugs/information-drug-class/influenza-flu-antiviral-drugs-and-related-information&gt; (2020).</Citation></Reference><Reference><Citation>Kumar, N. et al. Host-directed antiviral therapy. Clin. Microbiol. Rev.33, 10.1128/CMR.00168-19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227448</ArticleId><ArticleId IdType="pubmed">32404434</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin KK, Renzette N, Kowalik TF, Jensen JD. Antiviral drug resistance as an adaptive process. Virus Evol. 2016;2:vew014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5499642</ArticleId><ArticleId IdType="pubmed">28694997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect. Drug Resist. 2017;10:121–134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404498</ArticleId><ArticleId IdType="pubmed">28458567</ArticleId></ArticleIdList></Reference><Reference><Citation>Heaton BE, et al. A CRISPR activation screen identifies a pan-avian influenza virus inhibitory host factor. Cell Rep. 2017;20:1503–1512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5568676</ArticleId><ArticleId IdType="pubmed">28813663</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann HH, et al. TMEM41B is a pan-flavivirus host factor. Cell. 2021;184:133–148.e120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7954666</ArticleId><ArticleId IdType="pubmed">33338421</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimarco JD, et al. TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2. PLoS Pathog. 2021;17:e1009599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189496</ArticleId><ArticleId IdType="pubmed">34043740</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J, et al. Genome-wide CRISPR/Cas9 screen identifies host factors essential for influenza virus replication. Cell Rep. 2018;23:596–607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939577</ArticleId><ArticleId IdType="pubmed">29642015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider WM, et al. Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks. Cell. 2021;184:120–132.e114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7796900</ArticleId><ArticleId IdType="pubmed">33382968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, et al. A CRISPR-based screen identifies genes essential for West-Nile-virus-induced cell death. Cell Rep. 2015;12:673–683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4559080</ArticleId><ArticleId IdType="pubmed">26190106</ArticleId></ArticleIdList></Reference><Reference><Citation>Marceau CD, et al. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature. 2016;535:159–163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4964798</ArticleId><ArticleId IdType="pubmed">27383987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature. 2016;535:164–168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4945490</ArticleId><ArticleId IdType="pubmed">27383988</ArticleId></ArticleIdList></Reference><Reference><Citation>Puschnik AS, Majzoub K, Ooi YS, Carette JE. A CRISPR toolbox to study virus-host interactions. Nat. Rev. Microbiol. 2017;15:351–364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800792</ArticleId><ArticleId IdType="pubmed">28420884</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukhovny, A. et al. A CRISPR activation screen identifies genes that protect against Zika virus infection. J. Virol.93, 10.1128/JVI.00211-19 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675891</ArticleId><ArticleId IdType="pubmed">31142663</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, et al. Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection. Nat. Commun. 2020;11:164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6952391</ArticleId><ArticleId IdType="pubmed">31919360</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, et al. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. Nat. Commun. 2021;12:961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7878750</ArticleId><ArticleId IdType="pubmed">33574281</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, et al. Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection. Cell. 2021;184:76–91 e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574718</ArticleId><ArticleId IdType="pubmed">33147444</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, et al. Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. Nat. Genet. 2021;53:435–444.</Citation><ArticleIdList><ArticleId IdType="pubmed">33686287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesch M, et al. RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. PLoS Pathog. 2019;15:e1007601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422253</ArticleId><ArticleId IdType="pubmed">30883607</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathi S, et al. Meta- and orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding. Cell Host Microbe. 2015;18:723–735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829074</ArticleId><ArticleId IdType="pubmed">26651948</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez AA, et al. In vivo RNAi screening identifies MDA5 as a significant contributor to the cellular defense against influenza A virus. Cell Rep. 2015;11:1714–1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586153</ArticleId><ArticleId IdType="pubmed">26074083</ArticleId></ArticleIdList></Reference><Reference><Citation>Su WC, et al. Pooled RNAi screen identifies ubiquitin ligase Itch as crucial for influenza A virus release from the endosome during virus entry. Proc. Natl Acad. Sci. USA. 2013;110:17516–17521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808593</ArticleId><ArticleId IdType="pubmed">24101521</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlas A, et al. Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication. Nature. 2010;463:818–822.</Citation><ArticleIdList><ArticleId IdType="pubmed">20081832</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao L, et al. Drosophila RNAi screen identifies host genes important for influenza virus replication. Nature. 2008;454:890–893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574945</ArticleId><ArticleId IdType="pubmed">18615016</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins JW, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. 2014;505:691–695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4077721</ArticleId><ArticleId IdType="pubmed">24284630</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrosovich M, Herrler G, Klenk HD. Sialic acid receptors of viruses. Top. Curr. Chem. 2015;367:1–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7120183</ArticleId><ArticleId IdType="pubmed">23873408</ArticleId></ArticleIdList></Reference><Reference><Citation>White JM, Whittaker GR. Fusion of enveloped viruses in endosomes. Traffic. 2016;17:593–614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4866878</ArticleId><ArticleId IdType="pubmed">26935856</ArticleId></ArticleIdList></Reference><Reference><Citation>Paget J, et al. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project. J. Glob. Health. 2019;9:020421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6815659</ArticleId><ArticleId IdType="pubmed">31673337</ArticleId></ArticleIdList></Reference><Reference><Citation>Long JS, Mistry B, Haslam SM, Barclay WS. Host and viral determinants of influenza A virus species specificity. Nat. Rev. Microbiol. 2019;17:67–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">30487536</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanson KR, et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 2018;9:5416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6303322</ArticleId><ArticleId IdType="pubmed">30575746</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15:554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4290824</ArticleId><ArticleId IdType="pubmed">25476604</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulton BO, Palese P, Heaton NS. Replication-competent influenza B reporter viruses as tools for screening antivirals and antibodies. J. Virol. 2015;89:12226–12231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4645317</ArticleId><ArticleId IdType="pubmed">26401044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kizuka Y, Tonoyama Y, Oka S. Distinct transport and intracellular activities of two GlcAT-P isoforms. J. Biol. Chem. 2009;284:9247–9256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666577</ArticleId><ArticleId IdType="pubmed">19181664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumlin U, Olofsson S, Dimock K, Arnberg N. Sialic acid tissue distribution and influenza virus tropism. Influenza Other Respir. Viruses. 2008;2:147–154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941897</ArticleId><ArticleId IdType="pubmed">19453419</ArticleId></ArticleIdList></Reference><Reference><Citation>Stencel-Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS. The sweet spot: defining virus-sialic acid interactions. Nat. Rev. Microbiol. 2014;12:739–749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4791167</ArticleId><ArticleId IdType="pubmed">25263223</ArticleId></ArticleIdList></Reference><Reference><Citation>Anthony RM, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science. 2008;320:373–376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409116</ArticleId><ArticleId IdType="pubmed">18420934</ArticleId></ArticleIdList></Reference><Reference><Citation>Opat AS, van Vliet C, Gleeson PA. Trafficking and localisation of resident Golgi glycosylation enzymes. Biochimie. 2001;83:763–773.</Citation><ArticleIdList><ArticleId IdType="pubmed">11530209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitano M, et al. Rab11-mediated post-Golgi transport of the sialyltransferase ST3GAL4 suggests a new mechanism for regulating glycosylation. J. Biol. Chem. 2021;296:100354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7949161</ArticleId><ArticleId IdType="pubmed">33524390</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, et al. Enterovirus D68 receptor requirements unveiled by haploid genetics. Proc. Natl Acad. Sci. USA. 2016;113:1399–1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4747778</ArticleId><ArticleId IdType="pubmed">26787879</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm-Hansen CC, Midgley SE, Fischer TK. Global emergence of enterovirus D68: a systematic review. Lancet Infect. Dis. 2016;16:e64–e75.</Citation><ArticleIdList><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino TA, et al. The coxsackie-adenovirus receptor (CAR) is used by reference strains and clinical isolates representing all six serotypes of coxsackievirus group B and by swine vesicular disease virus. Virology. 2000;271:99–108.</Citation><ArticleIdList><ArticleId IdType="pubmed">10814575</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomeque J, et al. Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther. 2007;14:989–997.</Citation><ArticleIdList><ArticleId IdType="pubmed">17251988</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol. Ther. 2007;15:1504–1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">17565350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronzitti G, Gross DA, Mingozzi F. Human immune responses to adeno-associated virus (AAV) vectors. Front. Immunol. 2020;11:670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181373</ArticleId><ArticleId IdType="pubmed">32362898</ArticleId></ArticleIdList></Reference><Reference><Citation>Martino AT, Markusic DM. Immune response mechanisms against AAV vectors in animal models. Mol. Ther. Methods Clin. Dev. 2020;17:198–208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6965504</ArticleId><ArticleId IdType="pubmed">31970198</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard EL, et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 2021;39:717–726.</Citation><ArticleIdList><ArticleId IdType="pubmed">33536629</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaffer C. Mist begins to clear for lung delivery of RNA. Nat. Biotechnol. 2020;38:1110–1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">33020636</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao HK, et al. In vivo target gene activation via CRISPR/Cas9-mediated trans-epigenetic modulation. Cell. 2017;171:1495–1507.e1415.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5732045</ArticleId><ArticleId IdType="pubmed">29224783</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimarco JD, Heaton NS. From high-throughput to therapeutic: host-directed interventions against influenza viruses. Curr. Opin. Virol. 2022;53:101198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9086133</ArticleId><ArticleId IdType="pubmed">35030353</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss RB, et al. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J. Infect. Dis. 2012;206:1844–1851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3570175</ArticleId><ArticleId IdType="pubmed">23045618</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbott TR, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181:865–876.e812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189862</ArticleId><ArticleId IdType="pubmed">32353252</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins MF, Honorio-Ferreira A, Martins P, Goncalves CA. Presence of sialic acids in bronchioloalveolar cells and identification and quantification of N-acetylneuraminic and N-glycolylneuraminic acids in the lung. Acta Histochem. 2019;121:712–717.</Citation><ArticleIdList><ArticleId IdType="pubmed">31248580</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M, et al. Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virol. J. 2013;10:321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842836</ArticleId><ArticleId IdType="pubmed">24261589</ArticleId></ArticleIdList></Reference><Reference><Citation>Morise J, Takematsu H, Oka S. The role of human natural killer-1 (HNK-1) carbohydrate in neuronal plasticity and disease. Biochim. Biophys. Acta Gen. Subj. 2017;1861:2455–2461.</Citation><ArticleIdList><ArticleId IdType="pubmed">28709864</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front. Immunol. 2018;9:1869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099181</ArticleId><ArticleId IdType="pubmed">30150991</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulswit RJG, et al. Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Natl Acad. Sci. USA. 2019;116:2681–2690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377473</ArticleId><ArticleId IdType="pubmed">30679277</ArticleId></ArticleIdList></Reference><Reference><Citation>Alymova IV, et al. Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein. Glycobiology. 2012;22:174–180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255505</ArticleId><ArticleId IdType="pubmed">21846691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima K, et al. Amino acid substitutions contributing to alpha2,6-sialic acid linkage binding specificity of human parainfluenza virus type 3 hemagglutinin-neuraminidase. FEBS Lett. 2015;589:1278–1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5683071</ArticleId><ArticleId IdType="pubmed">25871520</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgione RE, et al. Structural basis for Glycan-receptor binding by mumps virus hemagglutinin-neuraminidase. Sci. Rep. 2020;10:1589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6994497</ArticleId><ArticleId IdType="pubmed">32005959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumm, R. E. &amp; Heaton, N. S. The development and use of reporter influenza B viruses. Viruses11, 10.3390/v11080736 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6723853</ArticleId><ArticleId IdType="pubmed">31404985</ArticleId></ArticleIdList></Reference><Reference><Citation>Morosky S, Lennemann NJ, Coyne CB. BPIFB6 regulates secretory pathway trafficking and enterovirus replication. J. Virol. 2016;90:5098–5107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4859712</ArticleId><ArticleId IdType="pubmed">26962226</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste MS, Nix WA, Maher K, Pallansch MA. Improved molecular identification of enteroviruses by RT-PCR and amplicon sequencing. J. Clin. Virol. 2003;26:375–377.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637088</ArticleId></ArticleIdList></Reference><Reference><Citation>You Y, Brody SL. Culture and differentiation of mouse tracheal epithelial cells. Methods Mol. Biol. 2013;945:123–143.</Citation><ArticleIdList><ArticleId IdType="pubmed">23097105</ArticleId></ArticleIdList></Reference><Reference><Citation>Savidis G, et al. The IFITMs inhibit Zika virus replication. Cell Rep. 2016;15:2323–2330.</Citation><ArticleIdList><ArticleId IdType="pubmed">27268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Curvall M, Lindberg B, Lonngren Structural studies of the capsular polysaccharide of Klebsiella type 81. Carbohydr. Res. 1975;42:73–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">166754</ArticleId></ArticleIdList></Reference><Reference><Citation>Santander J, et al. Mechanisms of intrinsic resistance to antimicrobial peptides of Edwardsiella ictaluri and its influence on fish gut inflammation and virulence. Microbiology. 2013;159:1471–1486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085987</ArticleId><ArticleId IdType="pubmed">23676433</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson, S. &amp; George, O. AAV production for serotypes with heparin binding capabilities., &lt;https://www.protocols.io/view/aav-production-for-serotypes-with-heparin-binding-82zhyf6&gt; (2020).</Citation></Reference><Reference><Citation>McClure, C., Cole, K. L., Wulff, P., Klugmann, M. &amp; Murray, A. J. Production and titering of recombinant adeno-associated viral vectors. J. Vis. Exp., e3348, 10.3791/3348 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3308604</ArticleId><ArticleId IdType="pubmed">22143312</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerch TF, et al. Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 A resolution. Structure. 2012;20:1310–1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3418430</ArticleId><ArticleId IdType="pubmed">22727812</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurnhammer C, et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum. Gene Ther. Methods. 2012;23:18–28.</Citation><ArticleIdList><ArticleId IdType="pubmed">22428977</ArticleId></ArticleIdList></Reference><Reference><Citation>Santry LA, et al. AAV vector distribution in the mouse respiratory tract following four different methods of administration. BMC Biotechnol. 2017;17:43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433059</ArticleId><ArticleId IdType="pubmed">28506256</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbert CL, Rutledge EA, Allen JM, Russell DW, Miller AD. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 2000;74:1524–1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111488</ArticleId><ArticleId IdType="pubmed">10627564</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>